Theravance Biopharma, Inc. (TBPH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Theravance Biopharma, Inc. (TBPH) is down 14.9% since the beginning of the year. At $16 per share, TBPH is trading 24.3% below its 52-week high of $21. Investors who bought $1,000 worth of TBPH shares 5 years ago would now be looking at an investment worth $961.

Theravance Biopharma, Inc. (TBPH) has returned -14.91% so far this year and 43.17% over the past 12 months. Over the last ten years, TBPH has returned -3.73% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since May 16, 2014, TBPH's average daily return is +0.04%, while the average monthly return is +0.76%. At this rate, an investment would double in approximately 7.6 years.

Historically, 47% of months were positive and 53% were negative. The best month was Jun 2014 with a return of +48.1%, while the worst month was Aug 2021 at -36.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, TBPH closed higher 50% of trading days. The best single day was Nov 11, 2025 with a return of +22.7%, while the worst single day was Aug 24, 2021 at -34.8%.

Theravance Biopharma, Inc. has an annualized alpha of -1.30%, beta of 0.88, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since May 19, 2014.

• This stock participated in 98.82% of S&P 500 Index downside but only 38.97% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TBPH ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Theravance Biopharma, Inc. (TBPH) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Theravance Biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Theravance Biopharma, Inc. was 84.09%, occurring on Sep 15, 2021. The portfolio has not yet recovered.

The current Theravance Biopharma, Inc. drawdown is 62.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Theravance Biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Theravance Biopharma, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.